Bio Pharma Dive
NOVEMBER 20, 2023
Called Evinova, the unit will operate as a separate business within AstraZeneca, which sees digital health solutions as a market primed for growth.
Pharmaceutical Technology
NOVEMBER 20, 2023
Takhzyro has been approved for the routine prevention of recurrent hereditary angioedema attacks in patients aged 2 years and older.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
NOVEMBER 20, 2023
The regulator plans to convene an advisory panel to discuss an expanded indication for Abecma, presenting another hurdle for Bristol Myers and partner 2seventy bio.
Pharmaceutical Technology
NOVEMBER 20, 2023
The value of haemophilia gene therapies like Roctavian and Hemgenix hinge on long-term efficacy and innovative payment structures play a key role.
Bio Pharma Dive
NOVEMBER 20, 2023
Biopharma companies capture data across a variety of different fronts and, so this data must be managed effectively in order to unlock business efficiencies and drive improvements.
Pharmaceutical Technology
NOVEMBER 20, 2023
AstraZeneca has launched a new digital health solutions business, Evinova, to expedite innovation in the life sciences industry.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
NOVEMBER 20, 2023
Serina Therapeutics’ polymer aims to overcome certain limitations of the commonly used polyethylene glycol for drug delivery.
Bio Pharma Dive
NOVEMBER 20, 2023
Several biotech companies, Biohaven among them, are trying to develop medicines that could trim the waistline while building lean tissue.
Pharmaceutical Technology
NOVEMBER 20, 2023
Wegovy has made headlines recently in the UK, highlighting both its seismic impact and changes in health habits.
XTalks
NOVEMBER 20, 2023
Food industry influencers were recently at the center of a controversy highlighted by the Federal Trade Commission (FTC). Last week, the FTC issued warning letters to two major groups in the food and beverage sector and several online food industry influencers. Their offense? Inadequate disclosure of paid social media posts that endorsed a sweetener and various sugary products.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
NOVEMBER 20, 2023
A team of researchers at Monash University received a $5m award from the government for developing CAR T cell therapy for prostate cancer.
Fierce Pharma
NOVEMBER 20, 2023
After blasting the U.K.’s drug pricing policy, the pharma industry has secured a new government spending deal featuring a higher revenue cap and an innovative drug-friendly rebate mechanism. | After blasting the U.K.’s drug pricing policy, the pharma industry has secured an improved government spending deal. The agreement will double the annual growth rate for prescription meds over the coming years.
Pharmaceutical Technology
NOVEMBER 20, 2023
Oxurion’s diabetic macular oedema drug, THR-149, failed to meet its primary endpoint in the Phase IIb trial.
Pharma Times
NOVEMBER 20, 2023
The centre will help discover new treatments to prevent, halt and cure the condition - News - PharmaTimes
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
NOVEMBER 20, 2023
NeoImmuneTech is developing NT-17, an IL-7 treatment, to promote rapid T-cell recovery in patients with acute radiation syndrome.
Intouch Solutions
NOVEMBER 20, 2023
In the rapidly changing landscape of global markets, staying ahead of the curve is crucial for businesses aiming to expand and thrive. As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors. There are the usual suspects like evolving provider models, the continued transition to value-based care and pharma/biotech companies increased investment in “access,” but there are two trends that ar
Pharmaceutical Technology
NOVEMBER 20, 2023
The EC has granted marketing authorisation to BeiGene’s Brukinsa plus obinutuzumab to treat follicular lymphoma (FL) in adults.
BioSpace
NOVEMBER 20, 2023
The buy brings three small molecules in preclinical development for Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage diseases into Merck’s pipeline.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
NOVEMBER 20, 2023
The partners will develop, manufacture, and commercialise the candidate outside China and adjacent territories.
Pharma Times
NOVEMBER 20, 2023
The OpenSAFELY platform will support the discovery of new treatments - News - PharmaTimes
BioSpace
NOVEMBER 20, 2023
The regulator has decided to hold an advisory committee meeting regarding BMS and 2seventy bio’s bid to move the CAR-T cell therapy into earlier lines of treatment, missing its previous target action date of Dec. 16.
pharmaphorum
NOVEMBER 20, 2023
The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in Germany next year.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioSpace
NOVEMBER 20, 2023
Quotient Therapeutics, co-located in Cambridge, Mass. and Cambridge, U.K., will receive $50 million over two years from Flagship to study somatic genomics with an eye to finding new targets for gene therapies.
Fierce Pharma
NOVEMBER 20, 2023
“AI is becoming part of the pharma fabric, and it really is set to disrupt the industry.” | Viz.ai’s Nina Binetti is joined by colleagues at CrowdPharm and Remedy Product Studio to explore the various ways in which AI is being used among pharma companies – from improving patient diagnoses and treatments to unlocking operating efficiencies.
XTalks
NOVEMBER 20, 2023
Today’s healthcare landscape is rapidly shifting, with an emphasis on the need for patient-centered care. Xtalks’ recent discussion with Rebekah Angove, PhD, Executive VP of Research and Evaluation at the Patient Advocate Foundation (PAF), offers a deeper understanding of incorporating patient narratives into clinical trials. Established over 25 years ago, the PAF has been dedicated to providing direct services to patients experiencing access and affordability challenges, especially those with c
BioSpace
NOVEMBER 20, 2023
The biotech company has bought the global rights to an investigational oral CDK2 inhibitor from Ensem Therapeutics in a licensing agreement valued at up to $1.33 billion if all milestones are met.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Fierce Pharma
NOVEMBER 20, 2023
It appears Bristol Myers Squibb’s multiple myeloma cell therapy Abecma will not end the year on a happy note. | It appears Bristol Myers Squibb’s multiple myeloma cell therapy Abecma will not end the year on a happy note. The company’s effort to gain approval for the CAR-T in an earlier line of treatment—previously set for an FDA decision on Dec. 16—will have to be pushed back pending an advisory committee meeting.
BioPharma Reporter
NOVEMBER 20, 2023
IO Biotech, Quotient Sciences and Terumo Blood and Cell Technologies are among the key companies welcoming new colleagues.
Fierce Pharma
NOVEMBER 20, 2023
The threat of microbial contamination has triggered yet another drug recall, this time from German pharma bigwig Bayer. | Bayer is recalling one lot of Vitrakvi oral solution in the U.S. after routine stability testing discovered the presence of microbial contamination identified as Penicillium brevicompactum.
Drug Discovery World
NOVEMBER 20, 2023
Raquel Sanches-Kuiper , Vice President of Science and Applications at Evonetix, and Clare Whitewoods , Marketing Communications Manager at Evonetix, look at the benefits synthetic DNA brings to pharmaceutical development. Engineering biology is reshaping the world, from enabling the rapid development of vaccines to providing alternatives to petroleum fuels.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
284 
Let's personalize your content